MOSCOW EXPERIENCE OF APPLICATION OF A NEW LONG-ACTING INSULIN ANALOGUE
- Authors: Demidov N.A1, Antsiferov M.B1,2
-
Affiliations:
- Moscovsky Town Hospital of the Moscow Healthcare Department
- Endocrinological Dispensary of the Moscow Healthcare Department
- Issue: No 4 (2018)
- Pages: 28-31
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295231
- ID: 295231
Cite item
Open Access
Access granted
Abstract
The purpose of this article is to analyze the results of the switch of patients with diabetes mellitus (DM) from insulin glargine 100 U/ml to glargine 300 U/ml. Methods. Using the Russian Federal Diabetes Register (RFDR), analysis of patients who received both medicines of glargine in 2016 and 2017 was performed. The dynamics of the main indicators was evaluated: the number of patients, age, body mass index, glycated hemoglobin levels, daily doses of two insulin glargines and prandial insulin preparations (when used). Results. According to the RFDR for Moscow, in 2016 glargine was received by 7,246 DM1 patients and 19,225 DM2 patients. In 2017, the number of DM1 patients receiving glargine increased by 15.1%, DM2 patients - by 23.1%. In 2017, the proportion of patients receiving glargine increased to 43.5% of DM1 patients and up to 30.8% of DM2 patients who received basal insulin. When transferring patients from glargine 100 U/ml to glargine of 300 U/ml, some improvement in glycemic control in DM2 patients was noted, while the transfer was not accompanied by a clinically significant increase in the dose of the drug. Conclusion. Patients highly appreciated the convenience of the improved injection pen for the administration of glargine 300 U/ml.
Keywords
Full Text
About the authors
N. A Demidov
Moscovsky Town Hospital of the Moscow Healthcare Department
Email: nicolay13@mail.ru
PhD, Endocrinologist Moscow, Russia
M. B Antsiferov
Moscovsky Town Hospital of the Moscow Healthcare Department; Endocrinological Dispensary of the Moscow Healthcare DepartmentMoscow, Russia
References
- Monami M., Marchionni N., Mannucci E. long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabet. Obes. Metab. 2009;11:372-78.
- Monami M., Marchionni N., Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a metaanalysis. Diabet. Res. Clin. Pract. 2008;81(2): 184-89.
- Becker R.H.A., Dahmen R., Bergmann K., et al. New insulin glargine 3000 Units. ml-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Unites.ml-1. Diabet. Care. 2015;38(4):637-43.
- Shiramoto M., Eto T., Irie S., el al. Singledose new insulin glargine 300 units/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabet. Obes. Metab. 2015;17(3):
- Baiey T., Dahmen R., Pettus J., Roussel R., et al. Insulin glargine 300 U/ml (gla-300) provides a more stable and flat pharmacodynamic/pharmacokinetic profile of at steady state compared to insulin degludec in patients with diabetes mellitus type 1. Endocr. Pract. Abstracts WCIRDC 18A. 2017;23(1).
- Home P.D., Bergenstail R.M., Bolli G.B., et al. New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabet. Care. 2015;38(12):2755-62.
- Анциферов М. Б. Клиническая характеристика и практические аспекты применения нового базального аналога инсулина глар гин 300 ЕД/мл Туджео Солостар. Фарматека. 2016;16:36-40.
Supplementary files
